Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E-test methodology.

× No keyword cloud information.

11 in total

1. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria.

Authors: C N Baker; S A Stocker; D H Culver; C Thornsberry
Journal: J Clin Microbiol Date: 1991-03 Impact factor: 5.948

Review 2. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Authors: Matthew E Falagas; Sofia K Kasiakou
Journal: Clin Infect Dis Date: 2005-03-22 Impact factor: 9.079

3. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.

Authors: Peter J Petersen; Ponpen Labthavikul; C Hal Jones; Patricia A Bradford
Journal: J Antimicrob Chemother Date: 2006-01-23 Impact factor: 5.790

4. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors: R L White; D S Burgess; M Manduru; J A Bosso
Journal: Antimicrob Agents Chemother Date: 1996-08 Impact factor: 5.191

Review 5. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.

Authors: James J Rahal
Journal: Clin Infect Dis Date: 2006-09-01 Impact factor: 9.079

Review 6. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors: Louis B Rice
Journal: Clin Infect Dis Date: 2006-09-01 Impact factor: 9.079

7. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.

Authors: María Eugenia Pachón-Ibáñez; Manuel Enrique Jiménez-Mejías; Cristina Pichardo; Ana Cristina Llanos; Jerónimo Pachón
Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191

8. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.

Authors: Marc H Scheetz; Chao Qi; John R Warren; Michael J Postelnick; Teresa Zembower; Arlene Obias; Gary A Noskin
Journal: Antimicrob Agents Chemother Date: 2007-02-16 Impact factor: 5.191

9. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.

Authors: Shiri Navon-Venezia; Azita Leavitt; Yehuda Carmeli
Journal: J Antimicrob Chemother Date: 2007-03-12 Impact factor: 5.790

10. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex.

Authors: Alexey Ruzin; David Keeney; Patricia A Bradford
Journal: J Antimicrob Chemother Date: 2007-03-15 Impact factor: 5.790

11 in total

1. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.

Authors: Luis A Arroyo; Ingeborg Mateos; Verónica González; Javier Aznar
Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191

2. Breakthrough bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline.

Authors: Sun Young Cho; Cheol-In Kang; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song; Jun Ho Jang
Journal: Antimicrob Agents Chemother Date: 2012-09 Impact factor: 5.191

3. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae.

Authors: Azza Elemam; Joseph Rahimian; Mehmet Doymaz
Journal: J Clin Microbiol Date: 2010-08-04 Impact factor: 5.948

4. Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains.

Authors: Ramamourthy Gopal; Young Gwon Kim; Jun Ho Lee; Seog Ki Lee; Jeong Don Chae; Byoung Kwan Son; Chang Ho Seo; Yoonkyung Park
Journal: Antimicrob Agents Chemother Date: 2013-12-23 Impact factor: 5.191

Review 5. Acinetobacter baumannii: emergence of a successful pathogen.

Authors: Anton Y Peleg; Harald Seifert; David L Paterson
Journal: Clin Microbiol Rev Date: 2008-07 Impact factor: 26.132

Review 6. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

Authors: Drosos E Karageorgopoulos; Theodore Kelesidis; Iosif Kelesidis; Matthew E Falagas
Journal: J Antimicrob Chemother Date: 2008-04-24 Impact factor: 5.790

Review 7. Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors: Helen Giamarellou; Garyphallia Poulakou
Journal: Drugs Date: 2009-10-01 Impact factor: 9.546

8. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.

Authors: Ryan K Shields; Cornelius J Clancy; Louise M Gillis; Eun J Kwak; Fernanda P Silveira; Rima C Abdel Massih; Gregory A Eschenauer; Brian A Potoski; M Hong Nguyen
Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240

9. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.

Authors: Luigi Principe; Silvia D'Arezzo; Alessandro Capone; Nicola Petrosillo; Paolo Visca
Journal: Ann Clin Microbiol Antimicrob Date: 2009-05-21 Impact factor: 3.944

Review 10. Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis.

Authors: Qianqian Liu; Wenzhang Li; Yulin Feng; Chuanmin Tao
Journal: PLoS One Date: 2014-06-09 Impact factor: 3.240